Rhea-AI Summary
Sensorion (ARNA) reported full-year 2025 results, provided a corporate update and released its annual report. Key clinical advances include SENS-501 six-month data expected Q1 2026 and SENS-601 (GJB2-GT) CTA submission targeted in H1 2026. The company completed a €60m private placement in Jan 2026, extending cash runway to end of H1 2027.
Financials: 2025 net loss of €29.4m, R&D expenses of €28.8m, and cash & equivalents of €47.5m as of Dec 31, 2025.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags